How should breakthrough bleeding be managed in a 37-year-old woman taking the combined oral contraceptive Jencycla (generic: combined oral contraceptive) and a GLP-1 agonist (glucagon-like peptide‑1 agonist)?

Management of Breakthrough Bleeding on Jencycla (Progestin-Only Pill)

For breakthrough bleeding on Jencycla (norethindrone progestin-only pill), first rule out pregnancy, infection, and medication interactions—particularly with the GLP-1 agonist—then treat with NSAIDs for 5-7 days if the patient wishes to continue the method. 1

Critical First Step: Clarify Jencycla Formulation

Jencycla is a progestin-only pill (POP) containing norethindrone, NOT a combined hormonal contraceptive 2. This is crucial because management differs significantly between POPs and combined pills.

Initial Assessment

Before treating breakthrough bleeding, systematically exclude:

• Pregnancy: POPs have higher failure rates than combined pills, and up to 10% of pregnancies on POPs are ectopic 2. Rule this out immediately, especially with any lower abdominal pain.

• Drug interactions: Check if the specific GLP-1 agonist affects contraceptive absorption. Tirzepatide specifically reduces oral contraceptive bioavailability due to delayed gastric emptying, particularly after the first dose 3. Other GLP-1 RAs (semaglutide, liraglutide, dulaglutide) do not show clinically significant interactions 4, 3. If on tirzepatide, consider switching to a non-oral contraceptive method.

• Infection or pathology: Rule out STIs, cervicitis, or uterine pathology if bleeding is heavy, prolonged, or associated with other symptoms 1.

• Other enzyme-inducing medications: Verify no concurrent use of rifampin, anticonvulsants, St. John's wort, or other CYP3A4 inducers 2.

Management Algorithm

If Patient Wants to Continue Jencycla:

First-line treatment: NSAIDs for 5-7 days 1

• Ibuprofen 400-600mg TID or naproxen 500mg BID
• This is the CDC-recommended approach for POPs with breakthrough bleeding
• May repeat as needed for recurrent episodes

If Breakthrough Bleeding Persists Beyond 3-4 Months:

Consider switching contraceptive methods rather than adding treatments, as irregular bleeding is common with POPs (occurs in a significant proportion of users) 2, 5:

1. Switch to combined hormonal contraceptive if no contraindications 6, 7

   • Reduces breakthrough bleeding from 40% (POPs) to 10% (CHCs) 7
   • Start with 30-35 mcg ethinyl estradiol formulation
   • Verify no cardiovascular risk factors (smoking, hypertension, thrombophilia, age >35 with vascular risks) 6

2. Switch to levonorgestrel IUD (Mirena)

   • Eliminates drug interaction concerns with GLP-1 agonists
   • Bleeding typically improves after initial 3-6 months

3. Switch to etonogestrel implant (Nexplanon)

   • Though breakthrough bleeding can occur, no oral absorption issues
   • NSAIDs remain treatment option if needed 1

Critical Pitfalls to Avoid

• Do not assume Jencycla is a combined pill: The management differs entirely from combined oral contraceptives. POPs have inherently higher rates of irregular bleeding 2.

• Do not miss ectopic pregnancy: Any persistent bleeding with abdominal pain requires immediate evaluation 2.

• Do not ignore the GLP-1 interaction: If the patient is on tirzepatide specifically, contraceptive efficacy may be compromised 3. Recommend backup barrier contraception or switch to non-oral method.

• Do not continue ineffective treatment beyond 3-4 months: Persistent breakthrough bleeding after this timeframe warrants method change, not prolonged expectant management 5.

Reassurance and Counseling

Irregular bleeding with POPs is expected and common, particularly in the first 3 months 2. However, if it persists or bothers the patient significantly, switching to a combined method (if medically appropriate) or an IUD provides better bleeding control 1, 7. The patient should understand that breakthrough bleeding does not indicate contraceptive failure if pills are taken correctly daily at the same time 2.